Correction
Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
-
* Corresponding author: Andrea H Bild andreab@genetics.utah.edu
1 Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA
2 Duke Institute for Genome Sciences & Policy, Duke University Medical Center, 2121 CIEMAS, Durham, NC 27701, USA
3 Lineberger Comprehensive Cancer Center, University of North Carolina, 102 Mason Farm Road, Chapel Hill, NC 27599, USA
4 Department of Genetics, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, USA
5 The Pulmonary Center, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA
6 Department of Pathology & Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
7 Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
8 Carolina Center for Genome Sciences, 5016 Genetic Medicine Building, University of North Carolina, Chapel Hill, NC 27599, USA
Breast Cancer Research 2011, 13:406 doi:10.1186/bcr2909
Published: 12 July 2011First paragraph (this article has no abstract)
In our previous publication [1], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [2,3]). It has recently been determined that the chemotherapy-response signatures in [2] are not reproducible, causing retraction of that article [3]. As such, the results presented in Figure 4 of our original paper [1] are no longer valid.